RBC Capital Reiterates a Buy Rating on Zimmer Biomet Holdings

By Ryan Adsit

In a report released yesterday, Glenn Novarro from RBC Capital reiterated a Buy rating on Zimmer Biomet Holdings (NYSE: ZBH), with a price target of $133. The company’s shares opened today at $119.20.

According to TipRanks.com, Novarro is a 5-star analyst with an average return of 10.7% and a 79.2% success rate. Novarro covers the Healthcare sector, focusing on stocks such as Integer Holdings Corporation, Boston Scientific Corp, and Varian Medical Systems.

Currently, the analyst consensus on Zimmer Biomet Holdings is Strong Buy and the average price target is $135.44, representing a 13.6% upside.

In a report issued on February 27, Canaccord Genuity also reiterated a Buy rating on the stock with a $144 price target.

Zimmer Biomet Holdings’ market cap is currently $24.03B and has a P/E ratio of 81.49. The company has a book value ratio of 2.4853.

Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. Last month, Katarzyna Mazur-Hofsaess, the Pres., Eur., M. East & Afr. of ZBH sold 44,195 shares for a total of $5,215,010.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zimmer Biomet Holdings, Inc. designs, manufactures and markets orthopaedic reconstructive products; sports medicine, extremities and trauma products; craniomaxillofacial and thoracic products; dental implants; and related surgical products. It operates through three major geographic segments: America, Europe and Asia Pacific. The Americas segment comprises principally of the U.S. and includes other North, Central and South American markets. The Europe segment comprises principally of Europe and includes the Middle East and African markets. The Asia Pacific segment comprises primarily of Japan and includes other Asian and Pacific markets. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.